PPARδ agonist comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-10-10. Where a claim depends on a specific study, the study is described rather than over-claimed.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
| Property | Value | Notes |
|---|---|---|
| Solubility | Soluble in dimethyl sulfoxide and some organic solvents; practically insoluble in water | Solvent choice affects laboratory handling |
| Typical storage | -20 °C, desiccated, protected from light | Common condition for research samples |
| Analytical method | Liquid chromatography–tandem mass spectrometry (LC-MS/MS) | Used for identification and quantification in biological or product samples |
| Common synonyms | GW501516, GW-501516, GSK-516, Endurobol | Names found in research and anti-doping literature |
| Regulatory status | Unapproved therapeutic; prohibited in competitive sport | Status can vary by country and context |
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
A common misconception is that cardarine has been proven safe for human use. In reality, human clinical data are limited, and long-term animal studies have raised concerns about cancer. Another misconception is that it is a supplement or vitamin-like compound. It is a synthetic research chemical with no approved medical indication. Scientific discussion often focuses on its mechanism and detection rather than therapeutic use. Regulatory and anti-doping literature treats it primarily as a prohibited substance.
Cardarine is explicitly prohibited by the World Anti-Doping Agency under the class of PPARδ agonists. Its presence in urine or blood samples can be detected using mass spectrometry-based methods, often liquid chromatography-tandem mass spectrometry. Athletes who test positive may face sanctions, including bans from competition. The compound is also regulated as a prescription-only or unapproved drug in many countries. Enforcement varies by jurisdiction, and some regions treat it as a controlled substance. Online sales may occur despite these restrictions, creating quality and legal risks.
Laboratory detection of cardarine typically involves sample preparation followed by chromatographic separation and mass spectrometric identification. Urine is the most common matrix for anti-doping tests, though blood and hair have also been explored. Methods can target the parent compound or its metabolites, depending on the expected window of detection. Reference standards are required for accurate quantification. Matrix effects and dilution can influence results, so laboratories use internal standards and validation protocols. The exact detection window varies with dose, route, and individual metabolism.
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
The two substrates of this enzyme are (5β)-pregnan-21-ol and oxidised nicotinamide adenine dinucleotide (NAD+). Its products are (5β)-pregnan-21-al, reduced NADH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is 21-hydroxysteroid:NAD+ 21-oxidoreductase. This enzyme is also called 21-hydroxysteroid dehydrogenase (NAD+).
Very Common (> 10% incidence) adverse effects Confusion Constipation (usually transient, but can persist in some) Decreased memory Diarrhea (usually transient, but can persist in some) Dry mouth ECG changes – usually benign changes in T waves Hand tremor (usually transient, but can persist in some) with an incidence of 27%. If severe, the psychiatrist may lower lithium dosage, change lithium salt type or modify lithium preparation from long to short-acting (despite lacking evidence for these procedures) or use pharmacological help Headache Hyperreflexia – overresponsive reflexes Leukocytosis – elevated white blood cell count Muscle weakness (usually transient, but can persist in some) Myoclonus – muscle twitching Nausea (usually transient) Polydipsia – increased thirst Polyuria – increased urination Renal (kidney) toxicity which may lead to chronic kidney failure, although some cases may be misattributed Vomiting (usually transient, but can persist in some) Vertigo Common (1–10%) adverse effects Acne Extrapyramidal side effects – movement-related problems such as muscle rigidity, parkinsonism, dystonia, etc. Euthyroid goitre – i.e. the formation of a goitre despite normal thyroid functioning Hypothyroidism – a deficiency of thyroid hormone. Common among bipolar patients; lithium increases rates. Hair loss/hair thinning Weight gain – 5% incidence, tends to start fast and then plateau. Usually ends at 1–2 kg. A 2022 systematic review and meta-analysis show an insignificant amount of weight gain of 0.462 kg, with higher weight gain associated with shorter use periods.
=== Historical cases === In 2000 an Australian mining company, South Blackwater Coal Ltd, with 400 employees, imposed drug-testing procedures. The trade unions advised their members to refuse to take the tests, partly because a positive result does not necessarily indicate present impairment. The workers were stood-down by the company without pay for a week. In 2003, sixteen members of the Chicago White Sox considered refusing to take a drug test, in hopes of making steroid testing mandatory. In 2006, Levy County, Florida, volunteer librarians resigned en masse rather than take drug tests. In 2010, Iranian super heavyweight class weightlifters refused to submit to a drug test authorized by the Iran Weightlifting League.
Sources: en.wikipedia.org
Ultralente insulin was a long-acting form of medical insulin, but not a true analogue. It had an onset of 4 to 6 hours, a peak effect between 14 and 24 hours, and a duration of 28 to 36 hours. In the mid-2000s, ultralente insulin, along with lente insulin, was discontinued in the United States due to decreasing use in favor of NPH insulin and newer insulin products. By 2011, the U.S. Food and Drug Administration (FDA) had officially withdrawn approval for ultralente insulin products.
Most corps have one. In general, western provinces with large non-Han population have more than those in China's interior. Corps are further subdivided at lower administrative levels. Regimental-level detachments (Chinese: 支队; pinyin: zhīduì) are found in provinces, prefectures, and specifically designated cities. Battalions (Chinese: 大队; pinyin: dadui) are located in districts of the important cities and counties. Companies (Chinese: 中队; pinyin: zhōngduì) are found in counties. All corps have subordinate elementary command colleges.
==== About Huntleigh Nesbit Evans (HNE) ==== In 1969, the Flowtron Aire Ltd, the predecessor of Huntleigh Healthcare, was founded in Luton in 1975 that of the Huntleigh Group Ltd. In 1985 the company's IPO took place as a Huntleigh Technology PLC at the London Stock Exchange. In 1993 Huntleigh took over the Nesbit Evans Group and operated as HNE HUNTLEIGH NESBIT EVANS.
=== Viruses === Viral infections make up perhaps one third of cases of food poisoning in developed countries. Norovirus is the leading cause of foodborne illness in the United States, responsible for approximately 58% of foodborne illnesses acquired domestically and about 50% of all foodborne disease outbreaks. Each year, norovirus causes an estimated 19 to 21 million illnesses and approximately 2,500 reported outbreaks in the United States, with outbreaks most common between November and April. Infected food workers are a frequent source of contamination, often through direct handling of ready-to-eat foods. Foodborne viral infections are usually of intermediate (1–3 days) incubation period, causing illnesses which are self-limited in otherwise healthy individuals.
Sources: en.wikipedia.org
== Skills == Skills a diener needs includes physical strength, reasoning, problem solving, attention to detail, and stress tolerance. In addition to the above skills, integrity/honesty, visual identification, flexibility, and reading are other important skills a diener should possess. Another skill is the ability to work with human remains, diagnostic tools, and surgical instruments involved in a death investigation. A diener is required to be knowledgeable of lab and safety techniques including the collection and preservation of evidence and any tasks involving any chemical, biological, microbiological, pathogenic and miscellaneous hazards.
Microfluidics allows for the isolation of individual cells for further analyses. The following principles outline the various microfluidic processes for single-cell separation: droplet-in-oil-based isolation, pneumatic membrane valving, and hydrodynamic cell traps. Droplet-in-oil-based microfluidics uses oil-filled channels to hold separated aqueous droplets. This allows the single cell to be contained and isolated from inside the oil-based channels. Pneumatic membrane valves manipulate air pressure to isolate individual cells by membrane deflection. The manipulation of the pressure source allows the opening or closing of channels in a microfluidic network. Typically, the system requires an operator and is limited in throughput.
=== Mechanism of action === Sabizabulin, as an orally available molecule, acts on microtubules, a component of the cytoskeleton. It binds to the colchicine binding site on the beta subunit of tubulin, as well as a novel site on the alpha subunit, and causes both to crosslink, thus depolymerizing microtubules and preventing their polymerization. By preventing mitotic spindle formation, this directly inhibits mitosis of tumor cells and endothelial cells attempting to form new blood vessels to feed them. In parallel, microtubule-mediated trafficking of cellular components (including androgen receptors into the nucleus), thus, a potential anti-androgen agent. The transport of viral particles (including SARS-CoV-2) may also be inhibited. These activities can inhibit viral replication and assembly. Inhibition of tubulin polymerization can also inhibit the release of pro-inflammatory cytokines and disrupt the activities of inflammatory cells.
In those with a body mass index (BMI) under 35, intra-abdominal body fat is related to negative health outcomes independent of total body fat. Intra-abdominal or visceral fat has a particularly strong correlation with cardiovascular disease. BMI and waist measurements are well recognized ways to characterize obesity. However, waist measurements are not as accurate as BMI measurements. Waist measurement (e.g., for BFP standard) is more prone to errors than measuring height and weight (e.g., for BMI standard). BMI will illustrate the best estimate of one's total body fatness, while waist measurement gives an estimate of visceral fat and risk of obesity-related disease. It is recommended to use both methods of measurements.
Ag+ + BH4− + 3 H2O → Ag0 +B(OH)3 +3.5 H2 The reduced metal atoms will form nanoparticle nuclei. Overall, this process is similar to the above reduction method using citrate. The benefit of using sodium borohydride is increased monodispersity of the final particle population. The reason for the increased monodispersity when using NaBH4 is that it is a stronger reducing agent than citrate. The impact of reducing agent strength can be seen by inspecting a LaMer diagram which describes the nucleation and growth of nanoparticles. When silver nitrate (AgNO3) is reduced by a weak reducing agent like citrate, the reduction rate is lower which means that new nuclei are forming and old nuclei are growing concurrently. This is the reason that the citrate reaction has low monodispersity. Because NaBH4 is a much stronger reducing agent, the concentration of silver nitrate is reduced rapidly which shortens the time during which new nuclei form and grow concurrently yielding a monodispersed population of silver nanoparticles. Particles formed by reduction must have their surfaces stabilized to prevent undesirable particle agglomeration (when multiple particles bond together), growth, or coarsening. The driving force for these phenomena is the minimization of surface energy (nanoparticles have a large surface to volume ratio).
Sources: en.wikipedia.org
It binds and activates PPARδ, a nuclear receptor that influences gene expression related to fatty acid metabolism and energy balance. This mechanism has been studied mainly in animals and cell models, not established as a safe human therapy.
No. It is not an anabolic-androgenic steroid; it is a synthetic PPARδ agonist. Because it is banned in sport, it is sometimes grouped with doping agents even though its chemical class differs from steroids.
Human data are limited and development was discontinued, so major effects and long-term risks are not well characterized. Some early studies examined metabolic markers, but they do not provide a basis for unsupervised use.
Cardarine is a common name for GW501516, a synthetic PPARδ agonist. It is not a steroid or a selective androgen receptor modulator. It was developed and studied as a research compound for metabolic pathways.